login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
EDITAS MEDICINE INC (EDIT) Stock News
USA
-
Nasdaq
- NASDAQ:EDIT -
US28106W1036
-
Common Stock
2.56
USD
-0.04 (-1.54%)
Last: 12/11/2025, 5:15:41 PM
2.57
USD
+0.01 (+0.39%)
After Hours:
12/11/2025, 5:15:41 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
EDIT Latest News, Press Relases and Analysis
All
Press Releases
a day ago - By: Zacks Investment Research
- Mentions:
BEAM
Editas (EDIT) Down 8.3% Since Last Earnings Report: Can It Rebound?
14 days ago - By: The Motley Fool
Editas (EDIT) Q2 2024 Earnings Call Transcript
20 days ago - By: Zacks Investment Research
- Mentions:
AZN
MRK
ADMA
AZN Wins FDA Nod for Expanded Use of Rare Disease Drug, Koselugo
21 days ago - By: Zacks Investment Research
- Mentions:
ADMA
COGT
ARQT
COGT Stock Skyrockets 120% in a Month: Here's What You Need to Know
23 days ago - By: Zacks Investment Research
- Mentions:
ILMN
PACB
NTLA
CRSP
...
Top 3 Genomics Stocks to Consider for Your Portfolio
a month ago - By: Zacks Investment Research
- Mentions:
ANRO
Is Alto Neuroscience, Inc. (ANRO) Outperforming Other Medical Stocks This Year?
3 months ago - By: Benzinga
Editas Medicine Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
a month ago - By: Zacks Investment Research
- Mentions:
ANIP
ADMA
ARQT
Editas Q3 Loss Narrower Than Expected, Revenues Increase Y/Y
a month ago - By: Zacks Investment Research
- Mentions:
DARE
Editas Medicine (EDIT) Reports Q3 Loss, Beats Revenue Estimates
a month ago - By: Editas Medicine, Inc.
Editas Medicine Announces Third Quarter 2025 Results and Business Updates
a month ago - By: Editas Medicine, Inc.
Editas Medicine Announces Third Quarter 2025 Results and Business Updates
a month ago - By: Zacks Investment Research
- Mentions:
JANX
Janux Therapeutics, Inc. (JANX) Reports Q3 Loss, Tops Revenue Estimates
a month ago - By: Editas Medicine, Inc.
Editas Medicine Announces EDIT-401 Poster Presentation at the American Heart Association (AHA) Scientific Sessions 2025
2 months ago - By: Benzinga
- Mentions:
XBI
ALNY
IBB
NTLA
...
Intellia Freezes Key Trial After Serious Liver Event, Stock Tumbles
2 months ago - By: Editas Medicine, Inc.
Editas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress
2 months ago - By: Editas Medicine, Inc.
Editas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress
2 months ago - By: Editas Medicine, Inc.
Editas Medicine Announces EDIT-401 Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress and Participation in Upcoming Investor Conferences
2 months ago - By: Editas Medicine, Inc.
Editas Medicine Announces EDIT-401 Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress and Participation in Upcoming Investor Conferences
3 months ago - By: Zacks Investment Research
- Mentions:
CRMD
KNSA
PHAR
Editas Nominates EDIT-401 as Lead In Vivo Therapy for High Cholesterol
3 months ago - By: Editas Medicine, Inc.
Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate
3 months ago - By: Editas Medicine, Inc.
Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate
4 months ago - By: Editas Medicine, Inc.
Editas Medicine to Host Webinar Announcing Lead In Vivo Development Candidate
4 months ago - By: Editas Medicine, Inc.
Editas Medicine to Host Webinar Announcing Lead In Vivo Development Candidate
4 months ago - By: Editas Medicine, Inc.
Editas Medicine to Participate in Upcoming Investor Conferences
4 months ago - By: Editas Medicine, Inc.
Editas Medicine to Participate in Upcoming Investor Conferences
4 months ago - By: The Motley Fool
Why Editas Medicine Stock Was Skyrocketing This Week
4 months ago - By: Zacks Investment Research
- Mentions:
DARE
Editas Medicine (EDIT) Reports Q2 Loss, Tops Revenue Estimates
4 months ago - By: Editas Medicine, Inc.
Editas Medicine Announces Second Quarter 2025 Results and Business Updates
4 months ago - By: Editas Medicine, Inc.
Editas Medicine Announces Second Quarter 2025 Results and Business Updates
4 months ago - By: Zacks Investment Research
- Mentions:
TCRX
TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Beats Revenue Estimates
Please enable JavaScript to continue using this application.